[Nuclear and cytoplasmic expressions of survivin in glioma and their prognostic value].
OBJECTIVE
To investigate the nuclear and cytoplasmic expressions of survivin in human glioma, and their correlations to clinicopathological characteristics and prognosis.


METHODS
A tissue microarray (TMA) based on 94 patients with glioma was constructed and then immunohistochemistry was used to examine the nuclear and cytoplasmic expressions of survivin in these glioma cohorts. Their correlations with clinicopathological characteristics and prognosis were analyzed.


RESULTS
Among the 94 samples of glioma, nuclear survivin was detectable in 21 (22.3%) cases and cytoplasmic survivin in 82 cases (87.2%). The positive rate of nuclear expression of survivin was significantly lower in grade I - II gliomas than in the grade III - IV gliomas (7.3% vs 34.0%, P = 0.005). Statistically significant associations were observed between nuclear survivin and recurrence (P = 0.031). Cytoplasmic expression of survivin was not related to any clinicopathological characteristics. The 5-year overall survival rate and 3-year progression-free survival rate were significantly lower in the nuclear survivin-positive group than in nuclear survivin-negative group (0% vs 39.50%, P < 0.001; 0% vs 27.52%, P = 0.021). The 5-year overall survival rate and 3-year progression-free survival rate in the cytoplasmic positive-group and negative-group were 43.60% vs 13.85% (P = 0.134), and 23.88% vs 0% (P = 0.965) respectively. A multivariate analysis was conducted according to the Cox regression model. The significantly independent prognostic factors for overall survival were nuclear expression of survivin, grade and age. The relative risk of death in the patients whose tumors were survivin positive compared with those whose tumors were survivin negative was 3.847.


CONCLUSIONS
Nuclear expression of survivin is correlated with glioma differentiation and recurrence. It is a negative prognostic factor for progression-free survival and overall survival in patients with glioma.
Pan
Yi
Y
Department of Radiation Oncology, Guangdong Provincial People's Hospital, Guangzhou 510080, China.
Hu
Wei-han
WH
Xie
Dan
D
Wu
Qiu-liang
QL
Liu
Yan-hui
YH
Xiang
Jin
J
Wu
Hui-xi
HX
D000293:Adolescent; D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000378:metabolism* / Q000473:pathology; D002467:Cell Nucleus / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D003593:Cytoplasm / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D005910:Glioma / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D051034:Inhibitor of Apoptosis Proteins / Q000096:biosynthesis; D008297:Male; D008869:Microtubule-Associated Proteins / Q000096:biosynthesis*; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D011379:Prognosis; D000077022:Survivin; D046888:Tissue Array Analysis / Q000379:methods
C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D000077022:Survivin